Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CollPlant Biotechnologies Ltd (NASDAQ: CLGN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. CollPlant files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents include press releases on financial results, product development updates, distribution agreements, corporate governance matters and interim financial statements.
Through its Form 6-K submissions, CollPlant furnishes materials such as quarterly financial results, condensed consolidated interim financial statements, operating and financial reviews, and detailed press releases on topics like expansion of rhCollagen distribution capabilities in North America, positive non-clinical data for its photocurable dermal and soft tissue filler, and distribution expansion for its Vergenix STR tendon-repair product in Europe. Filings also cover announcements related to scientific collaborations, including studies involving its Collink.3D rhCollagen-based bioink and Mayo Clinic’s fully humanized 3D bioprinted skin model, as well as notices of shareholder meetings and proxy materials.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand financial performance, progress in regenerative and aesthetic medicine programs, and material agreements such as CollPlant’s development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company. Real-time updates from EDGAR ensure that new 6-K and 20-F reports are available promptly.
Users can review CollPlant’s historical and current filings to analyze trends in its rhCollagen-based business, monitor disclosures about collaborations and product pipelines, and better understand the regulatory context of its 3D bioprinting, tissue repair and medical aesthetics activities.
CollPlant Biotechnologies Ltd director Alisa Lask reports existing equity awards, including options and restricted share units. She holds options to purchase 47,000 Ordinary Shares at an exercise price of $6.39 per share, expiring on May 2, 2032, all held directly.
The Form 3 also reports 10,000 restricted share units held directly. According to the footnotes, 3,125 of these units are vested and 6,875 will vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Of the options, 44,062 are already vested and 2,938 are scheduled to vest on May 2, 2026.
CollPlant Biotechnologies Ltd director Penn Elan has filed an initial Form 3 disclosing equity interests in the company. The filing reports options to purchase 10,000 ordinary shares at $4.02 expiring in 2028, 8,000 options at $6.39 expiring in 2030, and 24,000 options at $6.39 expiring in 2032, all held directly.
Elan also holds 7,500 restricted share units, of which 625 are already vested. The remaining 6,875 units vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on continued service. Most of the option grants are already fully vested or largely vested under the disclosed schedule.
CollPlant Biotechnologies director Avraham Havron has filed an initial statement of beneficial ownership, detailing his equity-based awards in the company. The filing reports options over 4,000 ordinary shares at an exercise price of $4.02 per share, expiring on January 14, 2028, which are fully vested and exercisable. It also reports options over 8,000 ordinary shares at $6.39 per share expiring on August 27, 2030, and options over 24,000 ordinary shares at $6.39 per share expiring on May 2, 2032, of which 22,500 are currently vested and the remaining 1,500 vest on May 2, 2026 subject to continued service. In addition, he holds 10,000 restricted share units, with 3,125 already vested and 6,875 scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, contingent on ongoing service.
CollPlant Biotechnologies Ltd executive Bagley Bowman, VP Commercial North America, filed an initial ownership report showing 25,000 restricted share units. These RSUs vest over four years: 25% on January 1, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter.
CollPlant Biotechnologies Ltd VP Legal Abelis Bar Berta filed an initial ownership report showing equity awards tied to company performance and continued service. The filing lists options to purchase 20,000 ordinary shares at an exercise price of $7.50 expiring on March 28, 2033, with 13,750 options already vested and 6,250 vesting in five equal quarterly installments from March 28, 2026 through March 28, 2027. It also reports 13,000 restricted share units, of which 5,686 are vested and 7,314 vest in nine equal quarterly installments between June 8, 2026 and June 8, 2028, plus a separate grant of 40,000 restricted share units vesting over three years, with 33% vesting on November 25, 2026 and the remaining 67% in eight equal quarterly installments thereafter.
CollPlant Biotechnologies Ltd VP of Product Development Jasmine Seror has filed an initial Form 3 outlining her equity-based holdings in the company. The filing lists several option grants to purchase Ordinary Shares and restricted share unit awards, all reported as directly owned.
Seror holds options over 4,000 and 1,000 Ordinary Shares with an exercise price of $4.0200 per share, and additional options over 5,000, 6,000 and 3,600 Ordinary Shares at $6.3900 per share, with expirations between 2027 and 2032. She also holds 12,000 restricted share units, of which 5,250 are vested and 6,750 vest in nine equal quarterly installments from June 8, 2026 to June 8, 2028, and a further 45,000 restricted shares vesting over three years, with 33% vesting on November 25, 2026 and the remaining 67% in eight equal quarterly installments. One option grant is described as fully vested and exercisable.
CollPlant Biotechnologies Ltd executive Philippe Bensimon reported his initial ownership in a Form 3. As VP Regulations and QA, he lists direct holdings of options to purchase ordinary shares in four grants covering 9,000, 15,000, 21,000 and 30,000 underlying shares at exercise prices of $4.0200 and $6.3900 per share. He also holds 2,000 ordinary shares, plus 30,000 restricted share units, of which 13,125 are already vested and the remaining 16,875 vest in nine equal quarterly installments from June 8, 2026 through June 8, 2028, subject to continued service.
CollPlant Biotechnologies Ltd VP Operations Oren Fahimipoor has reported his initial equity holdings in the company. He holds options to purchase 50,000 ordinary shares at an exercise price of $7.50 per share, expiring on March 28, 2033, with 34,375 options already vested and the remaining 15,625 vesting in five equal quarterly installments from March 28, 2026 through March 28, 2027, subject to continued service. He also holds 30,000 restricted share units, of which 13,125 are vested and 16,875 vest in nine equal quarterly installments from June 8, 2026 through June 8, 2028, also conditioned on continued service.
CollPlant Biotechnologies Ltd executive Rotem Eran, the Deputy CEO and CFO, filed an initial statement of beneficial ownership showing equity awards in the company. The filing lists several option grants to purchase Ordinary Shares, along with a block of restricted share units.
The holdings include options over 80,000 Ordinary Shares at an exercise price of $6.3900 per share expiring on January 27, 2032, 45,000 shares at $4.0200 expiring on December 26, 2027, 9,000 shares at $4.0200 expiring on May 18, 2028, and 52,707 shares at $6.3900 expiring on May 26, 2030, all reported as fully vested and exercisable where noted. Eran also holds 60,000 restricted share units, of which 26,250 are vested and 33,750 are scheduled to vest in nine equal quarterly installments from June 8, 2026 through June 8, 2028, subject to continued service.
CollPlant Biotechnologies reported that the Korean Patent Office has allowed a patent application covering key aspects of its photocurable dermal filler technology, which is based on the company’s recombinant human collagen (rhCollagen) platform and is currently under development for the aesthetic market.
The patent covers a polymerizable rhCollagen-based solution, combined with components such as a hyaluronic acid filler, injected into sub‑epidermal tissue and polymerized in situ using external light activation to form a supportive scaffold for tissue augmentation and contour stability. Patent protection is expected to extend through 2039.
The company notes that this Korean allowance follows a recently granted Japanese patent for related photocurable dermal filler compositions and adds to existing patent protection in the United States, Europe, China, Brazil, Australia, and Israel. CollPlant highlights that this technology targets the global injectable soft‑tissue filler market, which it cites as exceeding $6 billion.